J. Cole

发表

CYT003, a TLR9 agonist, in persistent allergic asthma – a randomized placebo‐controlled Phase 2b study

T. Casale, C. Vogelmeier, P. Saudan, 2015, Allergy.

Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study

R. Trivedi, L. Jacques, N. Gul, 2013, The clinical respiratory journal.

Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results

G. Ferguson, P. Barker, J. Cole, 2019, Journal of asthma and allergy.

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

P. Zeitlin, V. Shih, R. Olsson, 2018, Journal of asthma and allergy.

Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma

E. Kerwin, S. Spector, S. Wenzel, 2014 .

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.

Vinh Phu Nguyen, Marvin E Sexton, Zahid Ali Zafar, 2023, The Lancet. Respiratory medicine.

Tirzepatide Once Weekly for the Treatment of Obesity.

L. Aronne, I. Lee, J. Ard, 2022, The New England journal of medicine.

Single‐Use Autoinjector Functionality and Reliability for At‐Home Benralizumab Administration: GRECO Trial Results: 289

G. Ferguson, P. Barker, J. Cole, 2019, Journal of Allergy and Clinical Immunology.

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.

G. Yancopoulos, M. Bafadhel, S. Bhatt, 2023, The New England journal of medicine.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

I. Lee, J. Ard, J. Rosenstock, 2023, The Lancet.